Targeting Progesterone Signaling Prevents Metastatic Ovarian Cancer" was released in the journal PNAS.
This study is important to women who have the BRCA-1 mutation. Women with this mutation generally produce high levels of progesterone during their menstrual cycles. Targeting these women with an anti-progesterone medication may provide these high risk women with an alternative to prophylactic breast or ovarian surgery.
To find out more about this study, follow this link.